Responses to SMOi in medulloblastoma were previously reported and as expected, only patients with SHH pathway activation upstream SMO had on objective response.17,18,37–40 This highlights the importance of assessing SHH pathway alteration prior to SMOi treatment. The gene discussed is SHH; the disease is medulloblastoma.